It supports tissue repair, inflammation modulation, and regenerative signaling across muscles, tendons, ligaments, and the gut lining, making it a focus for research in angiogenesis research, injury tissue remodelling, and wellness
[14] The therapy is used off-label based on emerging science and clinical experience
Working with his PhD, student Martin Zarka, Bridge used his bioprocessing background to develop a manufacturing process for a proprietary form of GGC, now branded as Glyteine
10.1038/s41574-018-0059-4 Nat Rev Endocrinol
Originally published at the medium.com on March 29, 2017.